Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Dyslipidemia

Free Subscription Articles published in Circulation Retrieve available abstracts of 26 articles: HTML format

Single Articles

July 2026
1. VERGHESE D, Trujillo R, Abraham D, McClelland RL, et al
   Predictive Value of Coronary Artery Calcium Score From Nongated Chest CT Scans Compared With Gated Scans and Incidence of Cardiovascular Events.
   Circulation. 2026;154:302-312.
   PubMed     Abstract available
   
   
   
2. SWIFT DL, Ross LM, Laddu DR, Conroy MB, et al
   Role of Physical Activity in Obesity Treatment and Cardiometabolic Health: A Scientific Statement From the American Heart Association.
   Circulation. 2026;154:e1-e16.
   PubMed     Abstract available
   
   
   June 2026
3. KHAN SS, Bhave N, Blumenthal RS, Coresh J, et al
   Use of Predicted Risk and Expected Benefit to Guide Decision-Making in Cardiovascular-Kidney-Metabolic Syndrome for the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Ca
   Circulation. 2026 Jun 9. doi: 10.1161/CIR.0000000000001447.
   PubMed     Abstract available
   
   
   May 2026
4. WINTERS AH, Kelly MA, Syed MG, Bergquist T, et al
   A Genome-First Study of Familial Hypercholesterolemia Comparing African and European Ancestry Individuals.
   Circulation. 2026 May 29. doi: 10.1161/CIRCULATIONAHA.126.080694.
   PubMed     Abstract available
   
   
   
5. VEGA RB, O'Mahony G, Barbour AM, Yu H, et al
   Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for the Treatment of Hypercholesterolemia: Results From a Randomized, Single-Blind, Placebo-Controlled Phase 1 Trial in Treatment-Naive Patients.
   Circulation. 2026 May 15. doi: 10.1161/CIRCULATIONAHA.125.075973.
   PubMed     Abstract available
   
   
   April 2026
6. BLUMENTHAL RS, Morris PB, Gaudino M, Johnson HM, et al
   2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
   Circulation. 2026;153:e1154-e1276.
   PubMed     Abstract available
   
   
   March 2026
7. MARSTON NA, Bergmark BA, Prohaska TA, Moura FA, et al
   Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study.
   Circulation. 2026 Mar 30. doi: 10.1161/CIRCULATIONAHA.126.080012.
   PubMed     Abstract available
   
   
   January 2026
8. FEARON WF, Terada K, Takahashi K, Skoda A, et al
   Cardiac Allograft Vasculopathy Inhibition With Alirocumab: The CAVIAR Trial.
   Circulation. 2026;153:7-17.
   PubMed     Abstract available
   
   
   August 2025
9. LIU Y, Wang H, Yu M, Cai L, et al
   Hypertriglyceridemia as a Key Contributor to Abdominal Aortic Aneurysm Development and Rupture: Insights From Genetic and Experimental Models.
   Circulation. 2025 Aug 5:10.1161/CIRCULATIONAHA.125.074737.
   PubMed     Abstract available
   
   
   May 2025
10. WIEGMAN A, Peterson AL, Hegele RA, Bruckert E, et al
    Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial.
    Circulation. 2025 May 20. doi: 10.1161/CIRCULATIONAHA.124.073233.
    PubMed     Abstract available
    
    
    January 2025
11. CHEW NWS, Mehta A, Goh RSJ, Zhang A, et al
    Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach.
    Circulation. 2025;151:98-119.
    PubMed     Abstract available
    
    
    August 2024
12. DAMASE TR, Sukhovershin R, Godin B, Nasir K, et al
    Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia.
    Circulation. 2024;150:724-735.
    PubMed     Abstract available
    
    
    April 2024
13. TAMARGO IA, Baek KI, Xu C, Kang DW, et al
    HEG1 Protects Against Atherosclerosis by Regulating Stable Flow-Induced KLF2/4 Expression in Endothelial Cells.
    Circulation. 2024;149:1183-1201.
    PubMed     Abstract available
    
    
    February 2024
14. STONE NJ, Blum C
    If Action is Delayed, Is Survival Denied? Management of Severe Hypercholesterolemia Is Important and Urgent.
    Circulation. 2024;149:427-429.
    PubMed    
    
    
    January 2024
15. SANTOS RD, Cuchel M
    LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
    Circulation. 2024;149:363-366.
    PubMed    
    
    
    November 2023
16. YALCINKAYA M, Liu W, Thomas LA, Olszewska M, et al
    BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in Tet2 Clonal Hematopoiesis.
    Circulation. 2023;148:1764-1777.
    PubMed     Abstract available
    
    
    
17. MILES J, Scotti A, Castagna F, Kuno T, et al
    Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort.
    Circulation. 2023 Nov 16. doi: 10.1161/CIRCULATIONAHA.123.064566.
    PubMed     Abstract available
    
    
    October 2023
18. WIEGMAN A, Greber-Platzer S, Ali S, Doortje Reijman M, et al
    Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Circulation. 2023 Oct 20. doi: 10.1161/CIRCULATIONAHA.123.065529.
    PubMed     Abstract available
    
    
    
19. RAAL F, Durst R, Bi R, Talloczy Z, et al
    Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial.
    Circulation. 2023 Oct 18. doi: 10.1161/CIRCULATIONAHA.122.063460.
    PubMed     Abstract available
    
    
    September 2023
20. ALDANA-BITAR J, Karlsberg RP, Budoff MJ
    Letter by Aldana-Bitar et al Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1057.
    PubMed    
    
    
    
21. PEREZ DE ISLA L, Saltijeral Cerezo A, Mata P
    Response by Perez de Isla et al to Letter Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1059-1060.
    PubMed    
    
    
    
22. LONG X, Jiang M
    Letter by Long and Jiang Regarding Article, "Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia: The ARCHITECT Study".
    Circulation. 2023;148:1058.
    PubMed    
    
    
    July 2023
23. LAGU T, Schroth SL, Haywood C, Heinemann A, et al
    Diagnosis and Management of Cardiovascular Risk in Individuals With Spinal Cord Injury: A Narrative Review.
    Circulation. 2023;148:268-277.
    PubMed     Abstract available
    
    
    
24. JOHNS DG, Campeau LC, Banka P, Bautmans A, et al
    Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
    Circulation. 2023;148:144-158.
    PubMed     Abstract available
    
    
    May 2023
25. ZHANG Y, Dron JS, Bellows BK, Khera AV, et al
    Association of Severe Hypercholesterolemia and Familial Hypercholesterolemia Genotype With Risk of Coronary Heart Disease.
    Circulation. 2023;147:1556-1559.
    PubMed    
    
    
    April 2023
26. PEREZ DE ISLA L, Diaz-Diaz JL, Romero MJ, Muniz-Grijalvo O, et al
    Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Circulation. 2023 Apr 3. doi: 10.1161/CIRCULATIONAHA.122.062557.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum